Antje M. Richter

Giessen, HE 35390, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A Bioinformatics and Wet-Lab-Based Pipeline Identifies CLDN10 and GJB2 as Epigenetically Silenced Tumor Suppressor Genes in Cutaneous Melanoma.

A Bioinformatics and Wet-Lab-Based Pipeline Identifies CLDN10 and GJB2 as Epigenetically Silenced Tumor Suppressor Genes in Cutaneous Melanoma.

Journal: International journal of molecular sciences

Published: February 10, 2026

Epigenetic silencing and CRISPR-mediated reactivation of tight junction protein claudin10b (CLDN10B) in renal cancer.

Epigenetic silencing and CRISPR-mediated reactivation of tight junction protein claudin10b (CLDN10B) in renal cancer.

Journal: Clinical epigenetics

Published: November 01, 2024

Kv3.3 Expression Enhanced by a Novel Variant in the Kozak Sequence of KCNC3.

Kv3.3 Expression Enhanced by a Novel Variant in the Kozak Sequence of KCNC3.

Journal: International journal of molecular sciences

Published: October 25, 2024

Dual-Luciferase Reporter Assay for Prescreening CRISPR (d)Cas9-Mediated Epigenetic Editing on a Plant Promoter Using Human Cells.

Dual-Luciferase Reporter Assay for Prescreening CRISPR (d)Cas9-Mediated Epigenetic Editing on a Plant Promoter Using Human Cells.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: April 24, 2024

SIAH3 is frequently epigenetically silenced in cancer and regulates mitochondrial metabolism.

SIAH3 is frequently epigenetically silenced in cancer and regulates mitochondrial metabolism.

Journal: International journal of cancer

Published: January 18, 2024

Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function.

Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function.

Journal: Genes

Published: November 24, 2023

BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach.

BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach.

Journal: Genes

Published: July 28, 2023

Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner.

Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner.

Journal: Cancer gene therapy

Published: November 25, 2021

Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis.

Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis.

Journal: Cancers

Published: October 16, 2020

The ZAR1 protein in cancer; from epigenetic silencing to functional characterisation and epigenetic therapy of tumour suppressors.

The ZAR1 protein in cancer; from epigenetic silencing to functional characterisation and epigenetic therapy of tumour suppressors.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: June 21, 2020

RASSF10 Is a TGFβ-Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer.

RASSF10 Is a TGFβ-Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer.

Journal: Cancers

Published: November 25, 2019

Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function.

Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function.

Journal: Clinical epigenetics

Published: August 30, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026